[Long-term effects with ambrisentan monotherapy in patients with pulmonary arterial hypertension].

@article{Wen2014LongtermEW,
  title={[Long-term effects with ambrisentan monotherapy in patients with pulmonary arterial hypertension].},
  author={Li Wen and Xin Jiang and Pei An and Jing He and Lu Zheng and Qianqian Ben Liu and Fuhua Peng and Xiqi Xu and Zhi-Cheng Jing},
  journal={Zhonghua xin xue guan bing za zhi},
  year={2014},
  volume={42 6},
  pages={
          469-73
        }
}
OBJECTIVE To investigate long-term efficacy and safety of ambrisentan monotherapy in patients with pulmonary arterial hypertension (PAH). METHODS Patients with PAH who received 2.5 mg or 5 mg of ambrisentan once daily between July 10, 2011 and August 30, 2012 for at least 6 months were enrolled. The efficacy endpoints were change in exercise capacity, World Health Organization (WHO) functional class and N-terminal pro-brain natriuretic peptide (NT-proBNP) level, echocardiographic parameters… CONTINUE READING